I wore the world's first HDR10 smart glasses TCL's new E Ink tablet beats the Remarkable and Kindle Anker's new charger is one of the most unique I've ever seen Best laptop cooling pads Best flip ...

JDK 26 moves to general production availability. This short-term release is backed by six months of Premier-level support. Java Development Kit (JDK) 26, the latest standard Java release from Oracle, ...

Marc Santos is a Guides Staff Writer from the Philippines with a BA in Communication Arts and over six years of experience in writing gaming news and guides. He plays just about everything, from ...

Six weeks after tying up a mega-merger, Compass and Anywhere’s “cost synergies” have started to come into focus. Compass International Holdings said in a February filing with the New Jersey Department ...

Rogers Healy is out of the real estate game. The venture capitalist and residential real estate mogul has merged his Dallas-based brokerage, Rogers Healy and Associates Real Estate, into New ...

A Java library that collects JVM Native Memory Tracking (NMT) data via jcmd and exposes it as metrics through Micrometer and/or OpenTelemetry. NMT provides visibility into the JVM's native memory ...

At Rocket Pro’s 2026 Ignite event, the leadership team announced a three-year partnership with Compass International Holdings that adds up to 80 basis points in purchase pricing for borrowers who work ...

Apple’s AirTag is designed to help people keep track of personal belongings like keys, bags and luggage. But because AirTags and other Bluetooth trackers are small and discreet, concerns about ...

Compass Pathways has announced that its investigational psilocybin treatment has successfully met its primary endpoint in a second Phase 3 clinical trial moving it one step closer to FDA submission.

Phase 3 clinical trial data has been a success. COMP360 is the first traditional psychedelic to consistently deliver a highly statistically significant outcome. Results included maintaining a ...

COMP360 shows rapid symptom improvement in depression study COMP360 may compete with J&J's Spravato if approved Compass plans FDA meeting for rolling submission Feb 17 (Reuters) - Compass Pathways ...

Compass Pathways has reported another phase 3 win for its psilocybin therapy in treatment-resistant depression, sending the British biotech’s share price up 30% and teeing up talks about filing for ...